A Fundamental Commercial Disconnect
For commercial and scientific leaders across the IVD, molecular, and MedTech sectors, FDA clearance is often celebrated as the finish line. It is the culmination of years of research and millions of dollars poured into proving accuracy and clinical validity.
Yet, when field teams take these platforms to IDNs and health systems, they frequently face unexpected resistance. I remember using qPCR to quantify viral load for HIV. However, in my preliminary discussions, I found out that in addition to PMA clearance, infectious disease leads would evaluate adoption on operational integration, regulatory standards, and budgetary impact.
According to industry benchmarks and VAC evaluation metrics, over 60% of novel diagnostic technologies experience delayed adoption, conditional rejections, or extended pilot phases.1 The core issue is rarely the technology itself; it’s usually a fundamental commercial disconnect.
Core Reasons for VAC Delays & Rejections
- Reason 1: Clinical Data Without Health Economic Impact. Pitching diagnostic accuracy while failing to demonstrate cost savings or length-of-stay reductions.
- Reason 2: Workflow & EHR Bottlenecks. Introducing non-standard ordering or sample handling steps that overburden already strained clinical staff.
- Reason 3: Blanket Pitching Across Buyer Personas. Treating stakeholders as a monolith instead of tailoring value propositions to their priorities.
- Reason 4: Misalignment with Operational & Financial Metrics. Ignoring the financial constraints, payment shortfalls, and quality bonus structures that dictate hospital committee decisions.
Three Bottlenecks Slowing Institutional Diagnostic Adoption
-
The “Clinical Utility” Trap
Marketing teams routinely arm field reps with slide decks packed with sensitivity and specificity data, receiver operating characteristic (ROC) curves evaluating how well a test can distinguish between two outcomes (such as disease present vs. disease absent), and target amplification metrics.
While Chief Medical Officers (CMOs) care deeply about diagnostic accuracy, hospital CFOs navigate a stark economic reality: Medicare margins hover at negative levels, and operating expenses continue to rise sharply due to labor and supply costs. (The American Hospital Association reports that public payment shortfalls from Medicare and Medicaid totaled nearly $130 billion, with Medicare reimbursing hospitals at just 82 to 83 cents on the dollar.)
When a commercial pitch focuses strictly on “higher sensitivity” without detailing how that accuracy reduces length-of-stay (LOS), prevents uncompensated readmissions, or captures quality performance bonuses, the committee views the test purely as an added cost center.
-
Operational & EHR Hurdles
A diagnostic platform that requires a clinician to log into an external portal, manually re-enter patient demographics, or perform non-standard specimen preparation will encounter resistance.
PCPs and specialists face administrative overload. There is a need for EHR & laboratory information systems (LIS) Interoperability and seamless connectivity with LIS like Epic Beaker or Cerner Millennium. Tests must auto-populate discrete quantitative data into patient charts rather than outputting PDFs.
-
Uniform Pitch Across Diverse Buyers
A health system VAC consists of multiple decision-makers with differing priorities:
- The CFO focuses on margin impact, contribution revenue per bed-day, and net reimbursement timelines.
- The CMO focuses on clinical guidelines, risk reduction, and patient length of stay.
- The IT Committee focuses on EHR interface, cybersecurity, and interoperability.
- The Lab Director focuses on sample stability, batch processing, technician hands-on time, and resource demand.
Using uniform messaging with all these stakeholders ensures that critical institutional questions go unanswered.
A Four-Step Playbook for Institutional Messaging
For test adoption, commercial teams must use persona-specific messaging that bridges the gap between scientific accuracy and hospital operations.
Step 1: ROI with Focus on Total Cost of Care
Demonstrate that an intervention does not just work clinically, but lowers downstream expenses for the user (e.g., reducing 30-day hospital readmissions, length of stay, or ED utilization). Frame ROI around HEDIS, MIPS, and Length-of-Stay.
Ineffective Pitch: “Our automated patient outreach system sends SMS reminders to increase clinic appointments.”
Effective: Our platform automatically closes HEDIS care gaps like diabetic eye exams and mammograms via automated outreach, unlocking $250k+ in health plan quality bonus payouts.”
Step 2: CPOE: Streamlined EHR & Lab Protocol Integration
Increase efficiency by embedding test ordering directly into standard workflow.
Step 3: Tailored assets addressing concerns of CFO, CMO, CIO, and Lab
Step 4: Real-World Evidence (RWE) Pilot
Instead of asking a hospital system to commit to a full enterprise contract, a vendor should suggest an RWE Pilot outlining what metrics will be tracked, how long the trial will run, and what clinical or financial milestones will define success.
Executing the Strategy
Step 1: Build a Quantified Health-Economic Value Model
Replace generic clinical claims with a dynamic health-economic model tailored for risk-bearing entities (e.g., ACOs, capitated networks, or value-based care systems).
- Ineffective Pitch: “Our molecular assay detects Target X with 96% sensitivity.”
- Effective Pitch: “Implementing this rapid panel in the ED identifies high-risk candidates 14 hours faster, reducing average bed stay by 0.8 days and saving the facility $1,200 per patient.”
Connect test adoption directly to quality bonuses (e.g., HEDIS metrics, MIPS scores, or Star Ratings):
- Ineffective Pitch: “Our diagnostic platform features multi-marker assay technology that delivers high-throughput results with 99.8% precision, cutting lab processing time.”
- Effective Pitch: “Improving population screening and monitoring rates by just 5% preserves millions in value-based incentive payouts for a large health system.”
Step 2: Optimize for EHR and Phlebotomy Workflows
Address operational implementation during the initial VAC submission:
| Workflow Challenge | Traditional Pitch | Your Pitch |
| Test Ordering | “Physicians can order through our secure proprietary web portal.” | “We provide pre-built EHR order set templates (Epic/Cerner CPOE) that allow 1-click ordering within standard lab requisitions.” |
| Specimen Handling | “Requires specialized EDTA tubes kept at -20°C within 30 minutes.” | “Compatible with standard EDTA/SST blood collection tubes processed through standard daily courier pickups.” |
| Results Delivery | “PDF results emailed or faxed to the ordering physician.” | “Structured data returned directly into the EHR chart, flagging actionable findings for care coordinators.” |
Step 3: Deploy Stakeholder-Specific Commercial Toolkits
Equip field teams with messaging assets built explicitly for each committee stakeholder:
- CFO / Value Analysis Lead: Provide a 2-page Executive Budget Impact Model highlighting net reimbursement, cost-offsets, and 12-month ROI projections.
- Lab Director: Provide a Lab Operations Dossier detailing instrument footprint, hands-on technician time, calibration schedules, and reference lab integration protocols.
- CMO: Provide an Executive Summary emphasizing guideline alignment, clinical utility, risk reduction, and patient outcomes data.
Step 4: Utilize “Micro-Pilot” Risk-Sharing Frameworks
Health systems are risk-averse when evaluating innovative technologies. Overcome this hesitation by offering 60-90-day pilots with pre-defined success metrics:
- Define 3 to 4 KPIs for the pilot (e.g., 90% physician ordering compliance, 12-hour turnaround time, and a 15% reduction in follow-up procedures).
- Provide implementation support including nurse educators, IT integration specialists, and patient materials to lessen administrative burden on staff.
Bridging the Gap from Science to Revenue: How BTS Can Help
Developing a groundbreaking diagnostic or MedTech platform is a major scientific achievement but commercializing it requires an equally sophisticated go-to-market strategy. When messaging moves past scientific data dumps and directly solves the operational, financial, and administrative challenges facing health system leadership, institutional adoption follows.
Navigating the complexities of VACs, EHR integrations, and health-economic modeling does not have to slow your product launch. BTS specializes in helping diagnostic and life sciences organizations bridge the gap between regulatory clearance and revenue realization.
Whether you need to build dynamic budget impact models, craft stakeholder-specific toolkits, optimize CPOE workflows, or design RWE pilot frameworks that escape “pilot purgatory,” BTS is your strategic partner. We equip your marketing teams with insights, messaging, and operational strategies required to streamline sales cycles, secure approvals, and ensure your diagnostic innovations reach the patients who need them most.
Ready to accelerate your institutional market access? Contact BTS today to transform your VAC strategy.
By Brad Saeed, MS, MBA, Founder, President, & Lead Strategist
Brad is the founder and president of BTS Consulting, a life sciences strategy and marketing firm he launched in 2009 to solve a gap he experienced firsthand. As a former decision science project leader, he saw that most external support teams were either fluent in science or strong in marketing, but rarely both. With a background in molecular and cell biology and formal training in business strategy, Brad set out to bridge the divide between scientific innovation and effective market execution.
With over 20 years of industry experience, he began his career at the bench and has since led high-impact initiatives across pharmaceuticals, diagnostics, medical devices, and healthcare services. Brad is a seasoned strategist and science-driven content developer known for driving market acceptance of complex technologies. He is also a skilled grant writer and a respected voice at the intersection of science, strategy, and commercialization.
